Capital Group Growth ETF (CGGR)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
46.15 - Open
46.32 - Bid 46.54 x 160000
- Ask 46.55 x 190000
- Day's Range
46.14 - 46.60 - 52 Week Range
38.55 - 48.69 - Volume
1,513,703 - Avg. Volume
2,606,134 - Net Assets 26.01B
- NAV 46.14
- PE Ratio (TTM) 25.94
- Yield 0.15%
- YTD Daily Total Return 3.34%
- Beta (5Y Monthly) 1.29
- Expense Ratio (net) 0.39%
Performance Overview
View MoreTrailing returns as of 10/23/2026. Category is Large Growth.
Holdings
View MoreTop 10 Holdings (40.63% of Total Assets)
Sector Weightings
Recent News
View MoreResearch Reports
View More-
Lowering target price to $118.00
M/I HOMES INC has an Investment Rating of HOLD; a target price of $118.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
-
Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of the total revenue is generated in the United States.
-
Daily – Vickers Top Insider Picks for 09/11/2026
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
-
Boston Scientific Earnings: Competitive Pressure Closing in on Key Growth Areas
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
